{"id":1389,"date":"2026-11-18T12:38:53","date_gmt":"2026-11-18T10:38:53","guid":{"rendered":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/"},"modified":"2026-11-18T12:39:01","modified_gmt":"2026-11-18T10:39:01","slug":"ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/","title":{"rendered":"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP for conventional interventional trials, Annex 2 addresses how those principles apply when trials use decentralised elements, pragmatic design features or real-world data. For sponsors running trials in Greece and across the EU, it sets the reference point for designs that inspectors and ethics committees are increasingly seeing.<\/strong><\/p>\n\n<h2>What Annex 2 covers<\/h2>\n<p>Annex 2 supplements, rather than replaces, the E6(R3) principles and Annex 1. It covers three areas:<\/p>\n<ul>\n<li><strong>Decentralised elements:<\/strong> trial activities carried out away from the investigator site, such as remote visits, home nursing, direct-to-patient supply of investigational product and digital data collection tools.<\/li>\n<li><strong>Pragmatic elements:<\/strong> design features that bring a trial closer to routine care, such as broader eligibility, streamlined data collection and delivery within normal healthcare settings.<\/li>\n<li><strong>Real-world data:<\/strong> the use of data from sources such as electronic health records, registries and claims databases within an interventional trial.<\/li>\n<\/ul>\n\n<h2>Key expectations<\/h2>\n<ul>\n<li><strong>Risk-proportionate oversight.<\/strong> Oversight should be scaled to the risk each activity poses to participants and to the reliability of results, consistent with the quality-by-design approach of E6(R3).<\/li>\n<li><strong>Fitness for purpose of real-world data.<\/strong> Each data source should be assessed for relevance and reliability, and sponsors need appropriate, documented access to the data and its provenance, including where third parties hold it.<\/li>\n<li><strong>Remote consent with safeguards.<\/strong> Remote informed consent is acceptable where identity verification is planned in advance, and participants should have an alternative route.<\/li>\n<li><strong>Safety information that reaches investigators.<\/strong> When data flow from several sources, the sponsor must ensure that relevant safety information reaches investigators in a timely and usable way.<\/li>\n<li><strong>Clear roles.<\/strong> Home-care providers, technology vendors and data holders need defined responsibilities, contracts and oversight.<\/li>\n<\/ul>\n\n<h2>Implementation in the EU and US<\/h2>\n<p>ICH guidelines take effect once each regulator implements them. EMA will publish its own effective date for Annex 2, and FDA has not yet issued Annex 2 as final guidance. Sponsors should track both, and remember that in the EU, national requirements under the Clinical Trials Regulation, for example on home administration and direct-to-patient shipment, continue to apply alongside GCP.<\/p>\n\n<h2>Practical steps for sponsors<\/h2>\n<ul>\n<li>Map which decentralised or real-world data elements your protocols already use<\/li>\n<li>Update risk assessments and monitoring plans to cover off-site activities and data flows<\/li>\n<li>Review vendor contracts for data access, audit rights and safety reporting<\/li>\n<li>Check national requirements in each member state concerned before building a decentralised design<\/li>\n<\/ul>\n\n<h2>How PQRA helps<\/h2>\n<p>PQRA supports sponsors with clinical trial applications in Greece and the EU, GCP gap assessments against E6(R3), vendor oversight and safety reporting processes for trials that combine site-based, remote and real-world data elements.<\/p>\n<p><a href=\"\/el\/contact\/\">Contact PQRA about E6(R3) readiness<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP for conventional interventional trials, Annex 2 addresses how those principles apply when trials use decentralised elements, pragmatic design features or real-world data. For sponsors running trials in Greece and across [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1390,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials - PQRA\" \/>\n<meta property=\"og:description\" content=\"ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP for conventional interventional trials, Annex 2 addresses how those principles apply when trials use decentralised elements, pragmatic design features or real-world data. For sponsors running trials in Greece and across [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T10:38:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-18T10:39:01+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials\",\"datePublished\":\"2026-11-18T10:38:53+00:00\",\"dateModified\":\"2026-11-18T10:39:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/\"},\"wordCount\":462,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ich-e6r3-annex-2.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/\",\"name\":\"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ich-e6r3-annex-2.png\",\"datePublished\":\"2026-11-18T10:38:53+00:00\",\"dateModified\":\"2026-11-18T10:39:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ich-e6r3-annex-2.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/pqra-ich-e6r3-annex-2.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/","og_locale":"el_GR","og_type":"article","og_title":"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials - PQRA","og_description":"ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP for conventional interventional trials, Annex 2 addresses how those principles apply when trials use decentralised elements, pragmatic design features or real-world data. For sponsors running trials in Greece and across [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/","og_site_name":"PQRA","article_published_time":"2026-11-18T10:38:53+00:00","article_modified_time":"2026-11-18T10:39:01+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"2 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials","datePublished":"2026-11-18T10:38:53+00:00","dateModified":"2026-11-18T10:39:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/"},"wordCount":462,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ich-e6r3-annex-2.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/","url":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/","name":"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ich-e6r3-annex-2.png","datePublished":"2026-11-18T10:38:53+00:00","dateModified":"2026-11-18T10:39:01+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ich-e6r3-annex-2.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/11\/pqra-ich-e6r3-annex-2.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/ich-e6r3-annex-2-good-clinical-practice-for-decentralised-pragmatic-and-real-world-data-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=1389"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1389\/revisions"}],"predecessor-version":[{"id":1391,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/1389\/revisions\/1391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/1390"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=1389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=1389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=1389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}